[{"data":1,"prerenderedAt":205},["ShallowReactive",2],{"drug-sumatriptan":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":51,"contraindications":93,"warnings":103,"renal":104,"monitoring":105,"interactions":106,"review":107,"examples":110,"atc":116,"iran":118,"links":146,"populations":166,"usApproval":200},"sumatriptan",1,{"fa":7,"en":8},"سوماتریپتان","Sumatriptan","nervous-system",{"fa":11,"en":12},"تریپتان","Triptan",[14],{"name":15,"market":16},"Imitrex","US",[18,19,7,11],"imitrex","ایمیترکس",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-25","tablet","oral","25 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},25,"mg",false,[16],[32],{"source":33,"section":34},"fda-sumatriptan","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-50","50 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},50,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-100","100 mg tablet",{"amount":47,"unit":28,"perUnit":23,"scored":29},100,[16],[50],{"source":33,"section":34},[52,78],{"id":53,"disease":54,"label":55,"population":58,"type":62,"unit":28,"dose":63,"refs":64,"limits":67,"notes":71},"adult","migraine-acute",{"fa":56,"en":57},"حمله حاد میگرن — بزرگسال: ۲۵، ۵۰ یا ۱۰۰ mg","Acute migraine — adults: 25, 50 or 100 mg",{"minAge":59},{"value":60,"unit":61},18,"year","fixed",{"perDose":39,"dosesPerDay":5},[65],{"source":33,"section":66},"2.1",{"maxPerDay":68,"refs":69},200,[70],{"source":33,"section":66},[72],{"text":73,"refs":76},{"fa":74,"en":75},"۵۰ و ۱۰۰ mg ممکن است مؤثرتر از ۲۵ باشد ولی ۱۰۰ لزوماً بهتر از ۵۰ نیست. دوز دوم حداقل ۲ ساعت بعد؛ حداکثر ۲۰۰ mg در ۲۴ ساعت.","50 and 100 mg may be more effective than 25, but 100 not necessarily better than 50. Second dose at least 2 h later; max 200 mg\u002F24 h.",[77],{"source":33,"section":66},{"id":79,"disease":54,"label":80,"population":83,"type":85,"unit":28,"dose":86,"refs":90},"child",{"fa":81,"en":82},"زیر ۱۸ سال","Under 18 years",{"maxAge":84},{"value":60,"unit":61},"notCalculated",{"reason":87},{"fa":88,"en":89},"قرص سوماتریپتان برای زیر ۱۸ سال توصیه نمی‌شود.","Sumatriptan tablets are not recommended under 18 years.",[91],{"source":33,"section":92},"8.4",[94],{"id":95,"severity":96,"text":97,"refs":100},"cv","block",{"fa":98,"en":99},"بیماری ایسکمیک عروق کرونر، اسپاسم کرونر، سکته مغزی یا TIA، بیماری عروق محیطی، فشار خون کنترل‌نشده؛ همراه سایر تریپتان‌ها یا ارگوت در ۲۴ ساعت.","Ischemic coronary disease, coronary vasospasm, stroke or TIA, peripheral vascular disease, uncontrolled hypertension; other triptans or ergots within 24 h.",[101],{"source":33,"section":102},"4",[],[],[],[],{"status":108,"reviewer":109,"date":109},"unverified",null,[111],{"regimen":53,"formulation":36,"input":112,"expect":115},{"ageYears":113,"weightKg":114},30,70,{"perDose":39},[117],"N02CC01",{"status":119,"forms":120,"refs":141},"registered",[121,125,129,133,137],{"code":122,"en":123,"fa":124},"53224","SUMATRIPTAN 20MG 60 dose NASAL SPRAY","اسپری بینی سوماتریپتان ۲۰ میلی‌گرم ۶۰ دوز",{"code":126,"en":127,"fa":128},"10783","SUMATRIPTAN 12MG\u002F1ML 0.5ML AMP","آمپول سوماتریپتان ۱۲ میلی‌گرم \u002F ۱ میلی‌لیتر ۰٫۵ میلی‌لیتر",{"code":130,"en":131,"fa":132},"04963","SUMATRIPTAN 6MG\u002F1ML AMP","آمپول سوماتریپتان ۶ میلی‌گرم \u002F ۱ میلی‌لیتر",{"code":134,"en":135,"fa":136},"02005","SUMATRIPTAN SUCCINATE 100MG FC TAB","قرص روکش‌دار سوماتریپتان سوکسینات ۱۰۰ میلی‌گرم",{"code":138,"en":139,"fa":140},"02004","SUMATRIPTAN SUCCINATE 50MG FC TAB","قرص روکش‌دار سوماتریپتان سوکسینات ۵۰ میلی‌گرم",[142],{"source":143,"section":144,"url":145},"darooyab-generic","G-864\u002FSumatriptan","https:\u002F\u002Fwww.darooyab.ir\u002FG-864\u002FSumatriptan",[147,151,155,158,161,164],{"kind":148,"url":149,"label":150},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=219036","ANDA219036",{"kind":152,"url":153,"label":154},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=7a5f3bb3-147c-49b4-bd62-fdb4af775f8a","FDA Sumatriptan",{"kind":156,"url":157,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601116.html",{"kind":156,"url":159,"label":160},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa696023.html","Sumatriptan Injection",{"kind":162,"url":163,"label":117},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CC01",{"kind":165,"url":145,"label":8},"darooyab",{"pregnancy":167,"lactation":176,"pediatric":184,"geriatric":192},{"level":168,"text":169,"quote":172,"refs":173},"caution",{"fa":170,"en":171},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have not detected an increased frequency of birth defects or a consistent pattern of birth defects among women exposed to sumatriptan compared with the general population (see Data) .",[174],{"source":33,"section":175},"8.1",{"level":168,"text":177,"quote":180,"refs":181},{"fa":178,"en":179},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Sumatriptan is excreted in human milk following subcutaneous administration (see Data) .",[182],{"source":33,"section":183},"8.2",{"level":185,"text":186,"quote":189,"refs":190},"not-established",{"fa":187,"en":188},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[191],{"source":33,"section":92},{"level":168,"text":193,"quote":196,"refs":197},{"fa":194,"en":195},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.",[198],{"source":33,"section":199},"8.5",{"kind":201,"refs":202,"id":150},"ANDA",[203],{"source":33,"section":204},"SPL approval \u002F marketing category",1792191876558]